Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.51 |
| ▸ | PPARA | Q07869 | 16/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980394 | 0.94 | MAPT (0.47) | PPARGPPARAMAPTNPC1ALDH1A1 | |
| SCHEMBL3978914 | 0.87 | PPARG (0.59) | PPARGPPARAMAPT | |
| SCHEMBL5983436 | 0.85 | PPARG (0.50) | PPARGPPARAMAPTALDH1A1 | |
| SCHEMBL3972102 | 0.85 | PPARG (0.50) | PPARGPPARAMAPTALDH1A1 | |
| SCHEMBL3974895 | 0.82 | PTPN1 (0.53) | PPARGPPARAMAPTALDH1A1 | |
| SCHEMBL4673447 | 0.75 | MAPT (0.54) | MAPTNPC1ALDH1A1LMNACASP3 | |
| SCHEMBL3973596 | 0.73 | PPARG (0.67) | PPARGPPARAMAPT | |
| SCHEMBL3971525 | 0.71 | DGAT1 (0.54) | PPARGPPARAMAPTNPC1ALDH1A1 | |
| SCHEMBL3970004 | 0.70 | PPARG (0.64) | PPARGPPARANPC1CASP3RAB9A | |
| SCHEMBL3974615 | 0.69 | PPARG (0.68) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534894-B2 | Biphenyloxy-acids | WYETH (US) | 2009-05-19 | — | — | US | claimed |
| US-20060020003-A1 | Biphenyloxy-acids | WYETH (US) | 2006-01-26 | — | — | US | claimed |
| US-7534894-B2 | Biphenyloxy-acids | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1667959-A1 | BIPHENYLOXY-ACIDS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060020003-A1 | Biphenyloxy-acids | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2005030702-A1 | BIPHENYLOXY-ACIDS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020003-A1 | Biphenyloxy-acids | AHR, ARNT, NR1H4 | PPARG 88/4885PPARA 30/4885MAPT 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.